Sacituzumab Govitecan (Trodelvy)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses sacituzumab govitecan (Trodelvy), 180 mg lyophilized powder for solution for injection, for IV use. Indication: For the treatment of adult patients with unresectable, locally advanced or metastatic, HR-positive, human epidermal growth factor receptor 2-negative (immunohistochemistry [IHC] 0, IHC 1+ or IHC 2+/in situ hybridization-negative) breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the metastatic setting.